Xconomy -- Dicerna Pharmaceuticals, a Watertown, MA-based developer of RNA-interference drugs, has raised $5 million in a debt and options financing, according to an SEC filing. Doug Fambrough, who resigned from being a general partner at Boston’s Oxford Bioscience Partners last month to become CEO of Dicerna, told Xconomy at the time that he planned to raise a Series B round of funding for the company within the next few months.
